NASDAQ:ONVO Organovo (ONVO) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free ONVO Stock Alerts $1.03 -0.07 (-6.36%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.01▼$1.1250-Day Range$0.98▼$1.3552-Week Range$0.89▼$2.05Volume281,687 shsAverage Volume848,440 shsMarket Capitalization$10.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media Get Organovo alerts: Email Address Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About Organovo Stock (NASDAQ:ONVO)Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Read More ONVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONVO Stock News HeadlinesApril 18, 2024 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.comApril 15, 2024 | msn.comWhy Organovo Stock Is Up TodayApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 15, 2024 | reuters.comOrganovo's fatty liver disease drug meets main goal in mid-stage studyApril 15, 2024 | globenewswire.comOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to PlaceboFebruary 24, 2024 | benzinga.comOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning CallsFebruary 10, 2024 | finance.yahoo.comOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 9, 2024 | morningstar.comOrganovo Holdings Inc ONVOApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. February 9, 2024 | finance.yahoo.comONVO Continues ProgressFebruary 8, 2024 | sfgate.comOrganovo: Fiscal Q3 Earnings SnapshotFebruary 8, 2024 | msn.comOrganovo Holdings Unveils Corporate Presentation OnlineJanuary 25, 2024 | finance.yahoo.comOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis CongressJanuary 9, 2024 | finance.yahoo.comOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis CongressDecember 7, 2023 | finanznachrichten.deOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsDecember 6, 2023 | finance.yahoo.comOrganovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsNovember 13, 2023 | msn.comOVNO Continues Developing Breakthrough TreatmentsNovember 13, 2023 | finance.yahoo.comCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanNovember 11, 2023 | finance.yahoo.comOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)November 8, 2023 | finance.yahoo.comOrganovo Highlights FXR314 Combination Therapy Potential and PlanNovember 7, 2023 | msn.comONVO, FATH and BYU among mid-day moversOctober 10, 2023 | finance.yahoo.comONVO: A Company With Great Technology to Impact Health CareSeptember 8, 2023 | finance.yahoo.comOrganovo to Participate in the H.C. Wainwright Global Investment ConferenceAugust 25, 2023 | finance.yahoo.comIs Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapAugust 23, 2023 | finance.yahoo.comOrganovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataAugust 16, 2023 | msn.comOnvo receives $3 million grant from PennDOT to enhance electric vehicle charging infrastructureJuly 29, 2023 | seekingalpha.comONVO Organovo Holdings, Inc.See More Headlines Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/22/2024Next Earnings (Estimated)7/11/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,260,000.00 Net MarginsN/A Pretax Margin-7,885.54% Return on Equity-182.88% Return on Assets-138.52% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual Sales$370,000.00 Price / Sales27.95 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.59Miscellaneous Outstanding Shares10,040,000Free Float9,538,000Market Cap$10.34 million OptionableOptionable Beta0.91 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Keith E. Murphy (Age 52)Company Secretary & Executive Chairman Comp: $626.24kMs. Vaidehi Joshi (Age 38)Director of Discovery Biology & Director Comp: $91.4kMr. Thomas P. Hess CPA (Age 60)MBA, President & CFO Dr. Curtis M. Tyree Ph.D.Senior Vice President of Strategy & Business DevelopmentKey CompetitorsGenetic TechnologiesNASDAQ:GENESorrento TherapeuticsNASDAQ:SRNECoeptis TherapeuticsNASDAQ:COEPBioCardiaNASDAQ:BCDASenti BiosciencesNASDAQ:SNTIView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 300 shares on 2/2/2024Ownership: 0.000%David GobelSold 19,607 sharesTotal: $31,763.34 ($1.62/share)View All Insider TransactionsView All Institutional Transactions ONVO Stock Analysis - Frequently Asked Questions How have ONVO shares performed in 2024? Organovo's stock was trading at $1.11 at the start of the year. Since then, ONVO shares have decreased by 7.2% and is now trading at $1.03. View the best growth stocks for 2024 here. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) announced its quarterly earnings results on Thursday, February, 8th. The medical research company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01. The medical research company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.08 million. When did Organovo's stock split? Organovo shares reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONVO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
